DNER and plasma cell myeloma: Accordantly, in preclinical studies, BET inhibitors have shown extremely low-toxicity (Zuber et al., 2011, Asangani et al., 2014) but high efficacy in treating leukemia (Zuber et al., 2011), multiple myeloma (Delmore et al., 2011) and heart failure (Anand et al., 2013).